Safety of AS04‐HPV‐16/18 vaccine in Chinese women aged 26 years and older and long‐term protective effect in women vaccinated at age 18–25 years: A 10‐year follow‐up study
Fanghui Zhao,Archana Jastorff,Ying Hong,Shangying Hu,Wen Chen,Xiaoqian Xu,Yejiang Zhu,Jiahong Zhu,Xun Zhang,Wenhua Zhang,Dacheng Xu,Dali Wang,Rong Tang,Yonghong Sun,Yiping Shen,Qinjing Pan,Jian Yin,Daokuan Liu,Bin Liu,Naveen Karkada,Chunmei Jiang,Jianfeng Cui,Feng Chen,Jun Bi,Yuqing Bao,Xin Zhou,Cyrille Cartier,Yuemei Hu,Dorota Borys
DOI: https://doi.org/10.1111/ajco.13833
2022-09-17
Abstract:Graphical This figure elaborates on the clinical relevance of our findings in a form that could be shared with patients/individuals by healthcare professionals. Introduction The pivotal efficacy study assessed efficacy and safety of GSK's AS04‐HPV‐16/18 vaccine in Chinese women aged 18–25 years up to 6 years. The present extension study, performed 4 years later, offered AS04‐HPV‐16/18 vaccination to placebo recipients. Vaccine safety and its long‐term protective effect were assessed at Year 10. Methods All 6051 women who received AS04‐HPV‐16/18 or the placebo during the initial study (NCT00779766) were invited to phase III/IV, open‐label, partially controlled extension Year 10 study (NCT03629886). Placebo recipients were offered three‐dose AS04‐HPV‐16/18 vaccination and followed up over 12 months to assess the safety. Cervical samples from all women were examined. Vaccine efficacy (VE) against incident infections and cytological lesions associated with HPV‐16/18 and other oncogenic types was assessed as exploratory objective. Results Among 3537 women (out of 6051) enrolled in the extension study, 1791 women (mean age 32.7 years; standard deviation 1.8 years) received AS04‐HPV‐16/18 and reported no serious adverse events, potential immune‐mediated diseases, or adverse pregnancy outcomes related to vaccination. Among 6051 women, VE against incident HPV‐16, ‐18, and ‐16/18 infections up to Year 10 was 82.8% (95% confidence interval: 72.5–89.7), 79.8% (64.5–89.2), and 80.8% (72.4–87.0), respectively. VE against HPV‐16/18 ASC‐US+, CIN1+, and CIN2+ was 92.7% (82.2–97.7), 94.8% (67.4–99.9), and 90.5% (34.6–99.8), respectively. Conclusion AS04‐HPV‐16/18 vaccine showed an acceptable safety profile in Chinese women vaccinated at age 26 years or above, and a long‐term protection similar to other efficacy trials worldwide.
oncology